All In Biotech

Drug Trial Radar · NCT00554918

Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy

A Randomised Phase II Feasibility Study of Docetaxel (Taxotere®) Plus Prednisolone vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Strontium-89 vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) Plus Strontium-89 in Hormone Refractory Prostate Cancer Metastatic to Bone.

Last checked: Nov 19, 2026Latest source record: Aug 7, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Planned (sponsor's estimate)

Start

Feb 2005

Primary completion

Dec 2008

Study completion Jun 2013

Sponsor

Lead sponsor
University Hospital BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 7, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisolone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Zoledronic acid may help relieve some of the symptoms caused by bone metastases. Radioactive substances, such as strontium chloride Sr 89, may help relieve bone pain caused by prostate cancer. Giving docetaxel together with prednisolone with or without zoledronic acid and/or strontium chloride Sr 89 may kill more tumor cells. PURPOSE: This randomized phase II trial is studying the side effects and how well giving docetaxel together with prednisolone works with or without zoledronic acid and/or strontium chloride Sr 89 in treating patients with prostate cancer metastatic to bone that has not responded to hormone therapy.

Conditions

  • Metastatic Cancer
  • Prostate Cancer

Interventions

  • docetaxelDrug

  • prednisoloneDrug

  • zoledronic acidDrug

  • quality-of-life assessmentProcedure

  • strontium chloride Sr 89Radiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety
  2. Toxicity and tolerability of docetaxel and zoledronic acid
  3. Toxicity and tolerability of docetaxel and strontium chloride Sr 89
  4. Toxicity and tolerability of docetaxel, zoledronic acid, and strontium chloride Sr 89

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust

    Birmingham, England, United Kingdom

  • Gloucestershire Oncology Centre at Cheltenham General Hospital

    Cheltenham, England, United Kingdom

  • Gloucestershire Royal Hospital

    Gloucester, England, United Kingdom

  • Ipswich Hospital

    Ipswich, England, United Kingdom

  • Mid Kent Oncology Centre at Maidstone Hospital

    Maidstone, England, United Kingdom

  • Christie Hospital

    Manchester, England, United Kingdom

  • Royal Marsden - Surrey

    Sutton, England, United Kingdom

  • Walsall Manor Hospital

    Walsall, England, United Kingdom

  • Aberdeen Royal Infirmary

    Aberdeen, Scotland, United Kingdom

  • Ayr Hospital

    Ayr, Scotland, United Kingdom

  • Edinburgh Cancer Centre at Western General Hospital

    Edinburgh, Scotland, United Kingdom

  • Beatson West of Scotland Cancer Centre

    Glasgow, Scotland, United Kingdom

  • Crosshouse Hospital

    Kilmarnock, Scotland, United Kingdom

  • Wishaw General Hospital

    Wishaw, Scotland, United Kingdom

  • Velindre Cancer Center at Velindre Hospital

    Cardiff, Wales, United Kingdom

  • Glan Clwyd Hospital

    Rhyl, Denbighshire, Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.